August 07, 2025

AI Matches Resident Accuracy in Thyroid Imaging, Study Shows

ChatGPT-4 Vision analyzes thyroid ultrasound images with accuracy comparable to resident physicians, suggesting its potential use in real-time diagnostic support.

Conexiant

August 06, 2025

Fewer Risks with Unilateral Robotic Tonsil Surgery

Unilateral transoral robotic surgery for HPV-positive tonsillar squamous cell carcinoma is associated with fewer complications, shorter hospital stays, and comparable survival compared with bilateral surgery.

Conexiant

July 29, 2025

Chemo's Impact on Brain Explored

Neuroimaging detects reduced grey matter in multiple brain regions among breast cancer patients after chemotherapy, raising concern for long-term cognitive risks.

Conexiant

August 04, 2025

Near-Infrared Tool Improves Gland Detection in Thyroid Surgery

Fiber-based near-infrared autofluorescence improved parathyroid gland identification during thyroidectomy and bilateral parathyroid exploration.

Conexiant

July 28, 2025

Biportal and Uniportal Endoscopy Compared in Trial 

The trial investigates how biportal and uniportal endoscopic approaches differ in postoperative disability, imaging results, and recovery metrics for lumbar spinal stenosis.

Conexiant

July 01, 2025

Retinal Thickness Patterns Linked to ALS Risk

In a long-term cohort study, researchers found that specific retinal changes—thinner photoreceptor layers and thicker retinal pigment epithelium—were linked to a higher risk of developing amyotrophic lateral sclerosis, suggesting potential noninvasive biomarkers for early detection.

Conexiant

April 25, 2025

FDA Approves Penpulimab-kcqx for NPC

The FDA approved penpulimab-kcqx for first line and previously treated recurrent or metastatic non-keratinizing nasopharyngeal carcinoma.

Conexiant

May 09, 2025

Upper Face Filler Techniques Lack Standardization, Review

A new scoping review revealed significant variation in hyaluronic acid filler injection techniques for the facial upper third.

Conexiant

May 16, 2025

FDA Approves PD-1–Targeted Monoclonal Antibody for SCAC

The FDA has approved Zynyz (retifanlimab-dlwr) as the first programmed death receptor-1 inhibitor for first-line treatment of advanced squamous cell carcinoma of the anal canal.

Conexiant